Asymptomatic Mpox Detections Stay Uncommon Across Nonendemic Regions
A new meta-analysis in Emerging Infectious Diseases places the prevalence of asymptomatic monkeypox virus detections on a far lower footing than earlier estimates suggested. Across 16 eligible studies published between May 12, 2022, and September 13, 2024, the pooled prevalence was 1.0%, with a 95% prediction interval of 0.1%–11.2%.
The finding matters because mpox control has increasingly depended on identifying infections early, isolating symptomatic cases, and interrupting close-contact spread. In the current outbreak, most transmission in the United States has occurred person to person through sexual contact, primarily among gay, bisexual, and other men who have sex with men. At the same time, the biology of mpox leaves an open question: transmission can occur 1–4 days before symptom onset, but whether people who never develop symptoms can pass the virus onward remains unresolved.
A Narrower Estimate Than Earlier Reviews
This analysis focused on peer-reviewed studies published during the heart of the ongoing outbreak, rather than on older reports that mixed contemporary data with earlier outbreaks. That distinction is important for interpretation. A previous systematic review estimated a pooled prevalence of 10.2%, but many of the included studies predated the 2022 global outbreak, and one report came from an outbreak associated with a primate sanctuary in Cameroon. The newer dataset is more directly aligned with the epidemiology of the clade IIb outbreak that spread globally in 2022.
Investigators searched PubMed using terms tied to asymptomatic or non-lesion infections and MPXV, then screened additional studies through citations. From 1,299 articles identified, 16 met inclusion criteria after a stepwise review process. The final analysis therefore reflects a small but carefully filtered body of evidence, not a broad sweep of all mpox literature. The included designs were varied: 8 prospective cohort studies, 5 retrospective cohort studies, 2 cross-sectional studies, and 1 mixed cohort study.
How the Meta-analysis Was Built
Eligibility was deliberately restrictive. Studies had to involve adults, be conducted outside sub-Saharan Africa, use PCR testing, and explicitly include persons described as asymptomatic, clinically inapparent, without lesions, without rash, or otherwise free of physical symptoms. The review excluded ecologic studies, modeling papers, case-control studies that selectively sampled on MPXV status, studies without individual-level data, and studies that did not perform PCR testing.
That framework strengthens the clinical relevance of the pooled estimate. It also narrows the population to the settings most relevant to the ongoing outbreak in nonendemic regions, where testing practices and surveillance intensity differ from those in places with endemic circulation. The investigators also evaluated geographic region and study design as potential modifiers, using random-effects methods, a logit transformation, and a continuity correction for studies with zero events. Heterogeneity was quantified with the ι2 statistic.
Across the 16 studies, the geographic spread was broad within nonendemic settings. Three studies came from the United States, three from Belgium, two from Germany, and one each from Austria, Denmark, England, France, Italy, Japan, Spain, and Switzerland. Fourteen studies reported the number of male participants. Study size varied widely, from 25 participants in one cross-sectional study to 6,600 in another.
Why the Low Prevalence Still Leaves Open Questions
A pooled prevalence of 1.0% is reassuring, but it does not settle the issue of infectiousness. PCR positivity in a person without symptoms shows viral genetic material, not necessarily transmissible virus. That biological gap matters at the bedside and in public health practice, because a positive molecular test does not prove a person can sustain onward spread, while a negative test makes infectiousness highly unlikely in the sampled context.
The study’s own framing keeps that uncertainty front and center. Although asymptomatic detections appear uncommon, the work did not evaluate infectivity or transmission potential among asymptomatic persons. Mpox continues to circulate globally, and the viral dynamics that allow persistence remain poorly understood. In practical terms, that means silent infection may exist at the margins without necessarily driving the outbreak in the way symptomatic disease does.
The study design also explains why the estimate may be clinically conservative. In the United States, people are often tested when lesions are present, which creates a built-in bias toward symptomatic illness. If asymptomatic infections are missed because testing depends on lesions, their true prevalence could be underestimated. Yet the low pooled prevalence across multiple nonendemic settings argues against a large hidden reservoir of silent infection in the available literature.
Geographic and Design Differences Did Not Move the Estimate Much
Sensitivity analyses did not show substantial differences by geographic region or study design. The pooled result was broadly stable across the available settings, which lends some confidence that the low prevalence is not an artifact of one country, one sampling strategy, or one analytic framework.
Still, stability is not the same as certainty. The included studies were heterogeneous in design and recruitment, and the review itself acknowledges that the underlying effect estimates could vary in future samples drawn from similar populations. A wide prediction interval, stretching up to 11.2%, signals that individual settings could deviate meaningfully from the pooled estimate even if the average remains low.
For clinicians and public health teams, the most immediate implication is that asymptomatic mpox detection should not be assumed to be common in nonendemic regions. Contact tracing, lesion-based testing, and rapid recognition of symptomatic disease remain central. At the same time, surveillance strategies must still account for the biological possibility of pre-symptomatic spread and the unresolved question of silent transmission.
The Remaining Evidence Gap Is Infectivity
The key unanswered question is not whether asymptomatic PCR detections can occur. It is whether those detections represent meaningful transmission risk.
That gap is where the next wave of mpox research needs to go. Molecular detection alone cannot map onward spread, and the current analysis leaves infectivity unmeasured by design. Future studies will need to pair PCR surveillance with transmission-linked data if public health policy is going to move beyond prevalence and toward true risk stratification. Until then, the best-supported conclusion is restrained but useful: in nonendemic regions during the 2022–2024 outbreak period, asymptomatic MPXV detections were uncommon, and the clinical burden still appears to sit overwhelmingly with recognized symptomatic infection.